Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 383 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Pulmonary Hypertension Clear all

Conditions: Pulmonary Hypertension
Interventions: Albuterol, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: ubenimex, placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 28
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more

Conditions: Pulmonary Arterial Hypertension
Interventions: ACT-385781A (Actelion Epoprostenol), Flolan®; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: La Jolla, California • Aurora, Colorado • Durham, North Carolina + 4 more

Conditions: Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
Interventions: iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 33
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 21 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Esuberaprost, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more

Conditions: Hypertension, Pulmonary
Interventions: treprostinil inhalations, tadalafil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Stanford, California • Chicago, Illinois

Conditions: Pulmonary Artery Hypertension
Interventions: Metformin, Placebo, mHealth Intervention, Usual Care; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Nashvile, Tennessee

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Notapplicable; Other
Lead sponsor: Actelion; Industry
Eligibility: Not listed
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 105
States / cities: Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 51
States / cities: La Jolla, California • Los Angeles, California • Pasadena, California + 45 more

Conditions: Pulmonary Arterial Hypertension
Interventions: RVT-1201, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan plus Spironolactone, Ambrisentan plus Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
Interventions: Iloprost; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Pulmonary Arterial Hypertension PAH
Interventions: Exercise, Standard of Care; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Right Heart Failure, Pulmonary Hypertension
Interventions: Spironolactone and conivaptan; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Arterial Hypertension
Interventions: Sorafenib; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: Opsumit (macitentan); Drug
Lead sponsor: Actelion; Industry
Eligibility: Not listed
Enrollment: 2,686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 144
States / cities: Mobile, Alabama • Phoenix, Arizona • Fullerton, California + 117 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Injectable Product, Riociguat Pill; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Effect of Inhaled Albuterol in Pulmonary Hypertension

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

Onco-primary Care Networking to Support TEAM-based Care

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure

Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

OPsumit USers Registry

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH